Sage Therapeutics (United States)

American biopharmaceutical company in Cambridge, Massachusetts, founded in 2010 and listed on the Nasdaq until it was bought by Supernus Pharmaceuticals, which worked on medicines that act on brain signalling. Developed brexanolone, the first treatment approved in the United States specifically for postpartum depression, and zuranolone, an oral neuroactive steroid for the same condition developed with Biogen, together with programmes in essential tremor, Parkinson's disease and Huntington's disease.